Shopping Cart 0
Cart Subtotal
AED 0

Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Eisai Co Ltd (4523)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 10,2019: Eisai Center for Genetics Guided Dementia Discovery commences full-scale operation toward innovative dementia treatments with new drug discovery approach in Cambridge, Massachusetts

Jul 08,2019: Eisai forms PROTACs research collaboration

May 09,2019: Eisai commences venture investment business aimed at accelerating innovation in Drug Creation and Establishment of Ecosystem Platform

May 09,2019: Eisai and Allm enter into Capital and Business Alliance Agreement for ICT Healthcare Solutions

May 08,2019: Eisai and the UK Dementia Research Institute jointly launch new post-doctoral programme to accelerate Dementia research

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Eisai Co Ltd-Key Facts

Eisai Co Ltd-Key Employees

Eisai Co Ltd-Key Employee Biographies

Eisai Co Ltd-Major Products and Services

Eisai Co Ltd-History

Eisai Co Ltd-Company Statement

Eisai Co Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Eisai Co Ltd-Business Description

Product Category: Neurology Products

Overview

Performance

Product Category: Oncology Products

Overview

Performance

Product Category: Others

Performance

Product Category: Americas Pharmaceutical Business

Overview

Performance

Product Category: Asia and Latin America Pharmaceutical Business

Overview

Performance

Product Category: China Pharmaceutical Business

Overview

Performance

Product Category: EMEA Pharmaceutical Business

Overview

Performance

Product Category: Japan Pharmaceutical Business

Overview

Performance

Product Category: Other Business

Overview

Performance

R&D Overview

Eisai Co Ltd-Corporate Strategy

Eisai Co Ltd-SWOT Analysis

SWOT Analysis-Overview

Eisai Co Ltd-Strengths

Eisai Co Ltd-Weaknesses

Eisai Co Ltd-Opportunities

Eisai Co Ltd-Threats

Eisai Co Ltd-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Eisai Co Ltd, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 10, 2019: Eisai Center for Genetics Guided Dementia Discovery commences full-scale operation toward innovative dementia treatments with new drug discovery approach in Cambridge, Massachusetts

Jul 08, 2019: Eisai forms PROTACs research collaboration

May 09, 2019: Eisai commences venture investment business aimed at accelerating innovation in Drug Creation and Establishment of Ecosystem Platform

May 09, 2019: Eisai and Allm enter into Capital and Business Alliance Agreement for ICT Healthcare Solutions

May 08, 2019: Eisai and the UK Dementia Research Institute jointly launch new post-doctoral programme to accelerate Dementia research

May 08, 2019: Eisai and UK Dementia research institute jointly launch new post-doctoral programme to accelerate dementia research

Apr 24, 2019: Eisai selected as competitive ICT strategy company 2019

Jan 22, 2019: Eisai listed as Global 100 most sustainable corporation for the fourth time

Dec 12, 2018: GARDP, Eisai and Takeda join forces to identify new antibiotics

Nov 14, 2018: EISAI Receives IR GRAND PRIX award second IR GRAND PRIX award since 2006

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Eisai Co Ltd, Performance Chart (2015-2019)

Eisai Co Ltd, Ratio Charts

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Eisai Co Ltd, Key Facts

Eisai Co Ltd, Key Employees

Eisai Co Ltd, Key Employee Biographies

Eisai Co Ltd, Major Products and Services

Eisai Co Ltd, History

Eisai Co Ltd, Subsidiaries

Eisai Co Ltd, Joint Venture

Eisai Co Ltd, Key Competitors

Eisai Co Ltd, Ratios based on current share price

Eisai Co Ltd, Annual Ratios

Eisai Co Ltd, Annual Ratios (Cont...1)

Eisai Co Ltd, Annual Ratios (Cont...2)

Eisai Co Ltd, Interim Ratios

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Eisai Co Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Eisai Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Cassava Sciences Inc

Ono Pharmaceutical Co Ltd

Nippon Kayaku Co Ltd

Daiichi Sankyo Inc

Chugai Pharmaceutical Co Ltd

Astellas Pharma Inc

Mochida Pharmaceutical Co Ltd

Company Profile

Company Profile Title

Eisai Co Ltd (4523)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 10,2019: Eisai Center for Genetics Guided Dementia Discovery commences full-scale operation toward innovative dementia treatments with new drug discovery approach in Cambridge, Massachusetts

Jul 08,2019: Eisai forms PROTACs research collaboration

May 09,2019: Eisai commences venture investment business aimed at accelerating innovation in Drug Creation and Establishment of Ecosystem Platform

May 09,2019: Eisai and Allm enter into Capital and Business Alliance Agreement for ICT Healthcare Solutions

May 08,2019: Eisai and the UK Dementia Research Institute jointly launch new post-doctoral programme to accelerate Dementia research

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Eisai Co Ltd-Key Facts

Eisai Co Ltd-Key Employees

Eisai Co Ltd-Key Employee Biographies

Eisai Co Ltd-Major Products and Services

Eisai Co Ltd-History

Eisai Co Ltd-Company Statement

Eisai Co Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

Eisai Co Ltd-Business Description

Product Category: Neurology Products

Overview

Performance

Product Category: Oncology Products

Overview

Performance

Product Category: Others

Performance

Product Category: Americas Pharmaceutical Business

Overview

Performance

Product Category: Asia and Latin America Pharmaceutical Business

Overview

Performance

Product Category: China Pharmaceutical Business

Overview

Performance

Product Category: EMEA Pharmaceutical Business

Overview

Performance

Product Category: Japan Pharmaceutical Business

Overview

Performance

Product Category: Other Business

Overview

Performance

R&D Overview

Eisai Co Ltd-Corporate Strategy

Eisai Co Ltd-SWOT Analysis

SWOT Analysis-Overview

Eisai Co Ltd-Strengths

Eisai Co Ltd-Weaknesses

Eisai Co Ltd-Opportunities

Eisai Co Ltd-Threats

Eisai Co Ltd-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Eisai Co Ltd, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 10, 2019: Eisai Center for Genetics Guided Dementia Discovery commences full-scale operation toward innovative dementia treatments with new drug discovery approach in Cambridge, Massachusetts

Jul 08, 2019: Eisai forms PROTACs research collaboration

May 09, 2019: Eisai commences venture investment business aimed at accelerating innovation in Drug Creation and Establishment of Ecosystem Platform

May 09, 2019: Eisai and Allm enter into Capital and Business Alliance Agreement for ICT Healthcare Solutions

May 08, 2019: Eisai and the UK Dementia Research Institute jointly launch new post-doctoral programme to accelerate Dementia research

May 08, 2019: Eisai and UK Dementia research institute jointly launch new post-doctoral programme to accelerate dementia research

Apr 24, 2019: Eisai selected as competitive ICT strategy company 2019

Jan 22, 2019: Eisai listed as Global 100 most sustainable corporation for the fourth time

Dec 12, 2018: GARDP, Eisai and Takeda join forces to identify new antibiotics

Nov 14, 2018: EISAI Receives IR GRAND PRIX award second IR GRAND PRIX award since 2006

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Eisai Co Ltd, Performance Chart (2015-2019)

Eisai Co Ltd, Ratio Charts

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Eisai Co Ltd, Key Facts

Eisai Co Ltd, Key Employees

Eisai Co Ltd, Key Employee Biographies

Eisai Co Ltd, Major Products and Services

Eisai Co Ltd, History

Eisai Co Ltd, Subsidiaries

Eisai Co Ltd, Joint Venture

Eisai Co Ltd, Key Competitors

Eisai Co Ltd, Ratios based on current share price

Eisai Co Ltd, Annual Ratios

Eisai Co Ltd, Annual Ratios (Cont...1)

Eisai Co Ltd, Annual Ratios (Cont...2)

Eisai Co Ltd, Interim Ratios

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Eisai Co Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Eisai Co Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Cassava Sciences Inc

Ono Pharmaceutical Co Ltd

Nippon Kayaku Co Ltd

Daiichi Sankyo Inc

Chugai Pharmaceutical Co Ltd

Astellas Pharma Inc

Mochida Pharmaceutical Co Ltd